drugset / Trial / NCT01809886

Reversal With Sugammadex From Deep Neuromuscular Blockade Induced by Rocuronium in Children: Randomised Clinical Trial

NCT01809886

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this clinical trial is to prove that the administration of sugammadex at a dose of 4 mg/kg for counteracting deep blockage \[without train-of-four (TOF) ratio response and post-tetanic count (PTC) \< of 2 induced and maintained with Rocuronium in pediatric patients for short-term elective surgery.

Timeline

Start
2011-10
Primary completion
2013-10
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Neostigmine Other / unclassified 0.05 mg/kg
Subject Sugammadex Other / unclassified 4 mg/kg
Background Atropine Other / unclassified 0.025 mg/kg

Indications

No indication recorded.